Table 1.

Persistence and continuity of statin treatment analysed by Cox's proportional hazards model and a logistic regression model. Relative risk of discontinuation and odds ratio of continuity <80% by sex, age <45 years, age 75+ years and risk factor co-medication. The middle age group (i.e. 45–74 years) served as areference. (95% confidence intervals shown in brackets).

Variable	n	Persistence Relative risk of discontinuation	P	Continuity OR for low continuity (<80%)	P
Sex	3623	1.00 (0.89, 1.13)	0.98	1.10 (0.79, 1.53)	0.57
Age 0–44 years	247	2.24 (1.86, 2.71)	<0.001	0.46 (0.27, 0.78)	<0.01
Age 75+ years	168	1.15 (0.87, 1.53)	0.32	1.17 (0.47, 2.92)	0.74
Cardiovascular co-medication	2823	0.88 (0.77, 1.01)	0.07	1.33 (0.91, 1.95)	0.14
Insulin	98	1.43 (1.03, 1.98)	0.03	0.62 (0.26, 1.45)	0.27
Oral antidiabetics	193	1.05 (0.80, 1.38)	0.73	0.67 (0.35, 1.27)	0.22